There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) and Catalent (CTLT – Research Report) with bullish sentiments.
Hookipa Pharma (HOOK)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Hookipa Pharma yesterday and set a price target of $5.00. The company’s shares closed last Monday at $0.63, close to its 52-week low of $0.41.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Hookipa Pharma has an analyst consensus of Strong Buy, with a price target consensus of $5.13, representing a 699.2% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Catalent (CTLT)
In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on Catalent, with a price target of $58.00. The company’s shares closed last Monday at $53.63.
According to TipRanks.com, Dodge is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Catalent has an analyst consensus of Hold, with a price target consensus of $48.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOOK:
- Hookipa Pharma Updates on Business Priorities and Partnerships
- Hookipa Pharma Reports Material Impairments in Financials
- Hookipa Pharma Trims Workforce, Refocuses R&D Strategy
- Hookipa Pharma Regains Rights After Roche Terminates Agreement
- HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
